Effects of Initial Gleason Grade on Outcomes during Active Surveillance for Prostate Cancer-Reference-Cited by-同舟云学术

Effects of Initial Gleason Grade on Outcomes during Active Surveillance for Prostate Cancer

Published:2018-10 Issue:5 Volume:1 Page:386-394
ISSN:2588-9311
Container-title:European Urology Oncology
language:en
Short-container-title:European Urology Oncology

Author:

Masic Selma,Cowan Janet E.,Washington Samuel L.,Nguyen Hao G.,Shinohara Katsuto,Cooperberg Matthew R.,Carroll Peter R.

Publisher

Elsevier BV

Subject

Urology,Radiology Nuclear Medicine and imaging,Oncology,Surgery

Reference17 articles.

1. Trends in management for patients with localized prostate cancer, 1990-2013;Cooperberg;JAMA,2015

2. Active surveillance for the management of localized prostate cancer (Cancer Care Ontario guideline): American Society of Clinical Oncology clinical practice guideline endorsement summary;Chen;J Clin Oncol,2016

3. Sanda MG, Crispino T, Freedland S, et al. Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. American Urological Association. www.auanet.org/guidelines/clinically-localized-prostate-cancer-new-(aua/astro/suo-guideline-2017)

4. Radical prostatectomy or watchful waiting in early prostate cancer;Bill-Axelson;N Engl J Med,2014

5. Follow-up of prostatectomy versus observation for early prostate cancer;Wilt;N Engl J Med,2017

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Japanese clinical practice guidelines for prostate cancer 2023;International Journal of Urology;2024-07-30

2. Descriptive analysis of prostate cancer pathology data from diagnosis and surgery in men from the 45 and Up Study;Pathology;2024-02

3. The impact of genomic biomarkers on a clinical risk prediction model for upgrading/upstaging among men with favorable‐risk prostate cancer;Cancer;2024-01-27

4. Large cribriform glands (> 0.25 mm diameter) as a predictor of adverse pathology in men with Grade Group 2 prostate cancer;Histopathology;2023-11-27

5. Active surveillance should be considered for select men with Grade Group 2 prostate cancer;BMC Urology;2023-09-30